Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Yayoi Nakayama

Akito Shibuya

Masato Yoshikawa

Masaki Seto

Zenyu Shiokawa

Michiyo Mochizuki

Yusuke Tominari

Morihisa Saitoh

Tomohiro Seki

Yoshihisa Nakada

Kosuke Hidaka

Yasuo Nakagawa

Taisuke Kato

Koji Watanabe

Tsuneo Oda

Tsuyoshi Maekawa

Nobuyuki Takakura

Hideki Furukawa

Shizuo Kasai

Yusuke Sasaki

Yasufumi Miyamoto

Toshitake Kobayashi

Jumpei Aida

Yasuhiro Hirata

Seiji Miwatashi

Paul D Greenspan

Brian Scott Freeze

Yasufumi Wada

Taisuke Tawaraishi

Yuko Hitomi

Shumpei Murata

Naoyoshi Noguchi

Atsutoshi Okabe

Satoshi Sasaki

Norihito Tokunaga

Kazuaki Takami

Tomohiro Okawa

Shigemitsu Matsumoto

Masanori Okaniwa

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

Cyclic dinucleotide

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Growing community of inventors

Kanagawa, Japan

Yayoi Nakayama